4D Molecular Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 100.84 million compared to USD 107.49 million a year ago. Basic loss per share from continuing operations was USD 2.58 compared to USD 3.32 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.25 USD | -1.19% | -7.92% | +14.76% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.76% | 1.19B | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- FDMT Stock
- News 4D Molecular Therapeutics, Inc.
- 4D Molecular Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023